"Designing Growth Strategies is in our DNA"

U.S. Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, Neutropenia, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2022-2029

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI100990

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Prevalence of Key Diseases (Arthritis, Psoriasis, Neutropenia, Cancer), in the U.S.
    2. Pipeline Analysis, Key Players
    3. Regulatory Scenario
    4. Key Industry Developments - Partnerships, Mergers & Acquisitions
    5. Impact of COVID-19 on the Biosimilars Market
  5. U.S. Biosimilars Market Analysis, Insights and Forecast, 2018-2029
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Pegfilgrastim
      2. Monoclonal Antibodies
      3. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Neutropenia
        4. Others
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2021)
    2. Profiles of Players Operating in the Market (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (based on availability))
      1. Celltrion Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      2. Pfizer Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      3. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      4. Amgen Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      5. Viatris Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      6. Coherus BioSciences
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)     
      7. Samsung Bioepis
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      8. Other Players
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
  7. Strategic Recommendations
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Prevalence of Key Diseases (Arthritis, Psoriasis, Neutropenia, Cancer), in the U.S.
    2. Pipeline Analysis, Key Players
    3. Regulatory Scenario
    4. Key Industry Developments - Partnerships, Mergers & Acquisitions
    5. Impact of COVID-19 on the Biosimilars Market
  5. U.S. Biosimilars Market Analysis, Insights and Forecast, 2018-2029
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Pegfilgrastim
      2. Monoclonal Antibodies
      3. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Neutropenia
        4. Others
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2021)
    2. Profiles of Players Operating in the Market (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (based on availability))
      1. Celltrion Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      2. Pfizer Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      3. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      4. Amgen Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      5. Viatris Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      6. Coherus BioSciences
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)     
      7. Samsung Bioepis
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
      8. Other Players
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (based on availability)
  7. Strategic Recommendations
Read Less

Table 01: U.S. Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2018-2029

Table 02: U.S. Biosimilars Market Revenue (USD billion) Forecast, by Disease Indication, 2018-2029

Table 03: U.S. Biosimilars Market Revenue (USD billion) Forecast, by Autoimmune Diseases, 2018-2029

Table 04: U.S. Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2018-2029

U.S. Biosimilars Market
  • 2018-2029
  • 2021
  • 2018-2020
  • 105
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports